ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0816

Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting

Rieke Alten1, Xavier Mariette2, Rene-Marc Flipo3, Roberto Caporali4, Maya Buch5, Yusuf Patel6, Raimon Sanmarti7, Sara Marsal8, Michael Nurmohamed9, Hedley Griffiths10, Peter Peichl11, Bettina Bannert12, Adrian Forster13, Melanie Chartier14, Yedid Elbez15, Christiane Rauch16, Vadim Khaychuk17 and Karissa Lozenski17, 1Schlosspark-Klinik University, Berlin, Germany, 2Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, 3Centre Hospitalier Universitaire de France, Lille, France, 4Policlinico S. Matteo University, Pavia, Italy, 5University of Leeds, Leeds, United Kingdom, 6Hull Royal Infirmary, Hull, United Kingdom, 7Hospital Clínic de Barcelona, Barcelona, Spain, 8Hospital Universitari Vall d’Hebron, Barcelona, Spain, 9ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, 10Barwon Rheumatology Service, Geelong, Australia, 11Evangelical Hospital, Vienna, Austria, 12Universitätsspital Basel, Basel, Switzerland, 13Schulthess Klinik, Zürich, Switzerland, 14Bristol Myers Squibb, Rueil-Malmaison, France, 15Deepscover, Puteaux, France, 16Bristol Myers Squibb, Munich, Germany, 17Bristol Myers Squibb, Princeton, NJ

Meeting: ACR Convergence 2021

Keywords: Cohort Study, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic (b)DMARD for treatment of moderate-to-severe RA and is available in SC formulation, which may offer convenience benefits with efficacy similar to IV administration.2 ASCORE (NCT02090556) was a 2-year, observational, prospective, multicenter study of SC abatacept for treatment of RA in routine clinical practice.3 This post hoc analysis was conducted to determine if retention and efficacy of abatacept were impacted by disease duration and/or treatment line.

Methods: Eligible patients, aged ≥18 years, with active moderate-to-severe RA (ACR/EULAR 2010 criteria4) who were IV abatacept-naive and initiated SC abatacept 125 mg once weekly, were enrolled into 2 cohorts: bDMARD-naive patients and those with ≥1 prior bDMARD treatment failure. This post hoc analysis evaluated abatacept retention using Kaplan-Meier estimates, as well as disease activity scores (DAS28 [ESR]), CDAI and SDAI in patients with disease duration of ≤2, 3–5, 6–10 or >10 years, and in patients taking abatacept as first-line or ≥ second-line treatment.

Results: Table 1 shows baseline characteristics. Mean age increased with disease duration; other characteristics were comparable across groups. Retention proportions (95% CIs) at Month 24 were 0.50 (0.4, 0.5), 0.47 (0.4, 0.5), 0.51 (0.5, 0.5) and 0.46 (0.4, 0.5) in the ≤2, 3–5, 6–10 and >10 years’ duration groups, respectively. Proportion of patients (95% CI) with ≤2 years’ duration retaining treatment at Month 24 were 0.51 (0.4, 0.6) among those using abatacept as first-line treatment and 0.44 (0.3, 0.6) among those using abatacept as a ≥ second-line treatment (Figure 1). Proportions (95% CI) at Month 24 were 0.51 (0.5, 0.6), 0.57 (0.5, 0.6) and 0.52 (0.5, 0.6) in first-line patients and 0.43 (0.4, 0.5), 0.48 (0.4, 0.5) and 0.44 (0.4, 0.5) in ≥ second-line patients in the 3–5, 6–10 and >10 years’ duration groups, respectively. Mean (SE) changes from baseline in DAS28 (ESR) at Month 24 were –2.12 (0.205), –1.86 (0.151), –2.07 (0.140) and –2.05 (0.115) in the ≤2, 3–5, 6–10 and >10 years’ duration groups, respectively; respective mean (SE) changes in CDAI were –18.74 (1.604), –15.60 (1.099), –18.50 (1.038) and –17.68 (0.850); and respective mean (SE) changes in SDAI were –19.10 (1.873), –15.72 (1.345), –19.54 (1.103) and –17.07 (0.939).

Conclusion: In this post hoc analysis of the real-world ASCORE trial, patients with RA receiving abatacept in clinical practice as first-line therapy had better retention versus those receiving it as a ≥ second-line treatment, regardless of disease duration at baseline. Retention rates were similar across disease duration subgroups. Improvements in disease activity were seen in all duration subgroups, without consistently greater or lesser improvement seen with longer disease duration.

References:

1. Aletaha D, et al. Ann Rheum Dis 2019;78:1609–1615.

2. Genovese MC, et al. Arthritis Rheumatol 2011;63:2854–2864.

3. Alten R, et al. Ann Rheum Dis 2019;78(suppl 2):A1639.

4. Aletaha D, et al. Arthritis Rheum 2010;62:2569–2581.

Medical writing: Robert Coover (Caudex)

Original abstract © 2020 EULAR/BMJ


Disclosures: R. Alten, Abbvie, 1, Amgen, 1, Biogen, 1, Galapagos, 1, Gilead, 1, Janssen, 1, Lilly, 1, Novartis, 1, Pfizer, 1, Roche, 1, BMS, 1, Celltrion, 1; X. Mariette, BMS, 2, Galapagos, 2, Gilead, 2, GSK, 2, Janssen, 2, Pfizer, 2, UCB, 2; R. Flipo, Abbvie, 2, Janssen, 2, BMS, 2, Pfizer, 2, MSD, 2, Roche-Chugai, 2; R. Caporali, Abbvie, 2, 6, BMS, 2, 6, Celltrion, 2, 6, Fresenius Kabi, 2, 6, Lilly, 2, 6, Pfizer, 2, 6, UCB, 2, 6, Sanofi, 2, 6, Sandoz, 2, 6, Novartis, 6, MSD, 2, 6, Gilead Sciences, Inc., 2, 6, Galapagos NV, 2, 6, Roche, 2, 6, SamSung-Bioepis, 2, 6; M. Buch, AbbVie, 2, 5, 6, Gilead Sciences, 2, 5, 6, Pfizer Inc, 2, 5, 6, UCB, 2, 5, 6, Eli Lilly, 2, 5, 6, MSD, 2, 5, 6, Roche, 2, 5, Sanofi, 2, 5, 6; Y. Patel, None; R. Sanmarti, Abbvie, 6, BMS, 5, BMS, 6, Sandoz, 6, Pfizer, 6, Roche, 6, MSD, 6; S. Marsal, Bristol Myers Squibb, 5, 6, Pfizer, 2, 5, 6, UCB, 5, Roche, 5, 6, Sanofi, 2, 5, MSD, 5, 6, Galapagos, 2, 5, Janssen, 5, Novartis - Sandoz, 5, 6, AbbVie, 2, 5, Lilly, 5, 6, IMIDomics, 12, Executive role; M. Nurmohamed, Abbvie, 12, DSMB Member, Eli Lilly, 2, Celltrion, 2, GSK, 2, Novartis, 12, Researcher, Janssen, 6, Pfizer, 12, Researcher, Galapagos, 12, Researcher; H. Griffiths, AbbVie, 1, Lilly, 1, 6; P. Peichl, Novartis, 6; B. Bannert, Abbvie, 6; A. Forster, Mepha Pharma AG, 6, Gilead Sciences Switzerland SARL, 2, Grünenthal Pharma AG, 2; M. Chartier, Bristol Myers Squibb, 3, 11; Y. Elbez, Bristol Myers Squibb, 2; C. Rauch, Bristol Myers Squibb, 3, 11; V. Khaychuk, Bristol Myers Squibb, 3; K. Lozenski, Bristol Myers Squibb, 3.

To cite this abstract in AMA style:

Alten R, Mariette X, Flipo R, Caporali R, Buch M, Patel Y, Sanmarti R, Marsal S, Nurmohamed M, Griffiths H, Peichl P, Bannert B, Forster A, Chartier M, Elbez Y, Rauch C, Khaychuk V, Lozenski K. Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/analysis-of-abatacept-treatment-retention-and-efficacy-according-to-disease-duration-and-treatment-line-in-a-real-world-setting/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-abatacept-treatment-retention-and-efficacy-according-to-disease-duration-and-treatment-line-in-a-real-world-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences